Bacteriophage therapy against staphylococci

Acta Microbiologica et Immunologica Hungarica

Volumn 60, Issue 4, 2013, Pages 411-422

  Klem, József ^a   Dömötör, Dóra ^b   Schneider, György ^c   Kovács, Tamás ^b   Tóth, András ^a,d   Rákhely, Gábor ^a,d  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Department of Biotechnology Nanophage Therapy Center Enviroinvest Corporation   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

alternative antimicrobials; bacteriophage therapy; phage; Staphylococcus

Indexed keywords

ARTICLE; BACTERIOPHAGE; MEDICAL LITERATURE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT STAPHYLOCOCCUS; PROPHYLAXIS; VALIDATION PROCESS;

STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 84890092222     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/AMicr.60.2013.4.3     Document Type: Article

References (50)

1. Watkins, R.R., David, M.Z., Salata, R.A.: Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus. J Med Microbiol 61, 1179-1193 (2012).
2. van Hal, S.J., Jensen, S.O., Vaska, V.L., Espedido, B.A., Paterson, D.L., Gosbell, I.B.: Predictors of mortality in Staphylococcus aureus Bacteremia. ClinMicrobiol Rev 25, 362-386 (2012).
3. Rajan, S.: Skin and soft-tissue infections: Classifying and treating a spectrum. Cleve Clin J Med 79, 57-66 (2012).
4. Dryden, M.S.: Complicated skin and soft tissue infection. J Antimicrob Chemother 65, iii35-44 (2010).
5. Crum-Cianflone, N.F.: Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev 21, 473-494 (2008).
6. Ulu M., Ayaz, C., Celen, M.K.: A case report and literature review: osteomyelitis caused by community-associated methicillin resistant Staphylococcus aureus. J Infect Dev Count 5, 896-900 (2011).
7. Boucher, H., Miller, L.G., Razonable, R.R.: Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 51, S183-197 (2010).
8. Shirtliff, M.E., Mader, J.T.: Acute septic arthritis. Clin Microbiol Rev 15, 527-544 (2002). (Pubitemid 41184077)
9. Pletz, M.W., Burkhardt, O., Welte, T.: Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: Linezolid or vancomycin-Comparison of pharmacology and clinical efficacy. Eur J Med Res 15, 507-513 (2010).
10. Montanaro, L., Speziale, P., Campoccia, D., Ravaioli, S., Cangini, I., Pietrocola, G., Giannini, S., Arciola, C.R.: Scenery of Staphylococcus implant infections in orthopedics. Future Microbiol. 6, 1329-1349 (2011).
11. Chambers, S.T.: Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators. Internal Med J 35, S63-71 (2005). (Pubitemid 44933540)
12. Hadaway, L.: Short peripheral intravenous catheters and infections. J Infus Nursing 35, 230-240 (2012).
13. Shah, S.S., Smith, M.J., Zaoutis, T.E.: Device-related infections in children. Pediatr Clin North Am 52, 1189-1208 (2005). (Pubitemid 40961621)
14. Ortega, E., Abriouel, H., Lucas, R., Gálvez, A.: Multiple roles of Staphylococcus aureus enterotoxins: Pathogenicity, superantigenic activity, and correlation to antibiotic resistance. Toxins 2, 2117-2131 (2010).
15. Pinchuk, I.V., Beswick, E.J., Reyes, V.E.: Staphylococcal enterotoxins. Toxins 2, 2177-2197 (2010).
16. Dulon, M., Haamann, F., Peters, C., Schablon, A., Nienhaus, A.: MRSAprevalence in Euro-pean healthcare settings: A review. BMC Infect Dis 11, 138 (2011).
17. Barber, M.: Methicillin-resistant staphylococci. J Clin Pathol 14, 385-393 (1961).
18. st century-A clinical super-challenge. N Engl J of Med 360, 439-443 (2009).
19. Burkhardt, O., Pletz, M.W., Mertgen, C.-P., Welte, T.: Linezolid-The first oxazolidinone in the treatment of nosocomial MRSA pneumonia. Recent Pat Anti-infect Drug Disc 2, 23-30 (2007).
20. Baudoux, P., Lemaire, S., Denis, O., Tulkens, P.M., van Bambeke, F., Glupczynski, Y.: Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureuswith various resistance phenotypes. J Antimicrob Chemother 65, 1228-1236 (2010).
21. Bhavnani, S.M., Rubino, C.M., Hammel, J.P., Forrest, A., Dartois, N., Cooper, C.A., Korth-Bradley, J., Ambrose, P.G.: Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 56, 1065-1072 (2012).
22. Liu, Y., Cui, J., Wang, R., Wang, X., Drlica, K., Zhao, X.: Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J Antimicrob Chemother 56, 1172-1175 (2005). (Pubitemid 43009845)
23. Howden, B.P., Grayson, M.L.: Dumb and dumber-The potential waste of a useful antistaphylococcal agent: Emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 42, 394-400 (2006). (Pubitemid 43122319)
24. Kurlenda, J., Grinholc, M.: Alternative therapies in Staphylococcus aureus diseases. Acta Biochim Pol 59, 171-184 (2012).
25. Twort, F.W.: An investigation on the nature of ultra-microscopic viruses. Lancet 186, 1241-1243 (1915).
26. Bruynoghe, R., Maisin, J.: Essais de thérapeutique au moyen du bacteriophage. Comptes Rendus des Séances et Mémoires de la Société de Biologie 85, 1120-1121 (1921).
27. Straub, M.E., Applebaum, M.B.A.: Studies on commercial bacteriophage products. JAMA 100, 110 (1933).
28. Chanishvili, N.: Phage therapy-History from Twort and Herelle through Soviet experi-ence to current approaches. Adv Virus Res 83, (2012).
29. Villa, T.G., Veiga-Crespo, P.: Advantages and disadvantages in the use of antibiotics or phages as therapeutic agents. In: Enzybiotics: Antibiotic Enzyme, and Therapeutics. Eds Villa, T.G., Veiga-Crespo, P. JohnWiley & Sons, Inc. ISBN 978-0-470-37655-3, 2010, pp. 27-58.
30. Sulakvelidze, A., Kutter, E.: Bacteriophage therapy in humans. In: Bacteriophages: Biology and Applications. Eds Kutter, E., Sulakvelidze, A. Boca Raton, FL: CRC Press, 2005, pp. 377-428.
31. Burman, L.G., Lundblad, G., Cammer, P., Fange, R., Lundborg, M., Soder, P.: Lysozyme-An enzyme of both historical and current interest as a therapeutical agent. Lakartidningen 88, 3665-3668 (1991).
32. Shearman, C.A., Jury, K.L., Gasson, M.J.: Controlled expression and structural organization of a Lactococcus lactis bacteriophage lysin encoded by two overlapping genes. Appl and Environ Microbiol 60, 3063-3073 (1994). (Pubitemid 24272327)
33. Ibrahim, H.R., Aoki, T., Pellegrini, A.: Strategies for new antimicrobial proteins and peptides: Lysozyme and aprotinin as model molecules. Curr Pharm Des 8, 671-693 (2002). (Pubitemid 34498558)
34. Touch, V.S., Hayakawa, K., Fukada, Y., Aratani, Sun, Y.: Preparation of antimicrobial reduced lysozyme compatible in food applications. J Agric Food Chem 51, 5154-5161 (2003).
35. Delfini, C., Cersosimo, M., Del Prete, V., Strano, M., Gaetano, G., Pagliara, A., Ambrò, S.: Resistance screening essay of wine lactic acid bacteria on lysozyme: Efficacy of lysozyme in unclarified grape musts. J Agric Food Chem 52, 1861-1866 (2004).
36. Hermoso, J.A., Garcia, J.L., Garcia, P.: Taking aimon bacterial pathogens: fromphage therapy to enzybiotics. Curr Opin Microbiol 10, 461-472 (2007). (Pubitemid 350064581)
37. Nau, R., Eiffert, H.: Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 15, 95-110 (2002). (Pubitemid 34052584)
38. Wentworth, B.B.: Bacteriophage typing of the Staphylococci. Bacteriol Rev 27, 253-272 (1963).
39. Kwan, T., Liu, J., DuBow, M., Gros, P., Pelletier, J.: The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc Natl Acad Sci USA 102, 5174-5179 (2005).
40. Belcaid, M., Bergeron, A., Poisson, G.: Mosaic graphs and comparative genomics in phage communities. J Comput Biol 17, 1315-1326 (2010) doi: 10.1089/cmb.2010.0108">10.1089/cmb.2010.0108
41. obocka, M., Hejnowicz, M.S., Dbrowski, K., Gozdek, A., Kosakowski, J., Witkowska, M., Ulatowska, M.I., Weber-Dbrowska, B., Kwiatek, M., Parasion, S., Gawor, J., Kosowska, H., Glowacka, A.: Genomics of staphylococcal Twort-like phages-Potential therapeutics of the post-antibiotic era. Adv Virus Res 83, 143-216 (2012).
42. O'Flaherty, S., Ross, R.P., Flynn, J., Meaney, W.J., Fitzgerald, G.F., Coffey, A.: Isolation and characterization of two anti-staphylococcal bacteriophages specific for pathogenic Staphylococcus aureus associated with bovine infections. Lett ApplMicrobiol 41, 482-486 (2005). (Pubitemid 41735619)
43. Matsuzaki, S., Yasuda, M., Nishikawa, H., Kuroda, M., Ujihara, T., Shuin, T., Shen, Y., Jin, Z., Fujimoto, S., Nasimuzzaman, M.D., Wakiguchi, H., Sugihara, S., Sugiura, T., Koda, S., Muraoka, A., Imai, S.: Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187, 613-624 (2003). (Pubitemid 36250025)
44. Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., Iannelli, D.: Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51, 2765-2773 (2007). (Pubitemid 47206211)
45. "Eliava Institute." [Online]. Available:
46. Duckworth, D.H., Gulig, P.A.: Bacteriophages: potential treatment for bacterial infections. BioDrugs 16, 57-62 (2002). (Pubitemid 34303968)
47. Brüssow, H.: What is needed for phage therapy to become a reality in Western medicine Virology 434, 138-142 (2012).
48. Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., Lavigne, R., Volckaert, G., Mattheus, W., Verween, G., De Corte, P., Rose, T., Jennes, S., Zizi, M., De Vos, D., Vaneechoutte, M.: Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PloS One 4, e4944 (2009).
49. Verbeken, G., Pirnay, J.-P., De Vos, D., Jennes, S., Zizi, M., Lavigne, R., Casteels, M., Huys, I.: Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp 60, 161-172 (2012).
50. st century phage therapy. Nat Biotechnol 22, 31-36 (2004). (Pubitemid 38057949)